Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma

Cancer Research

Volumn 63, Issue 2, 2003, Pages 287-289

  Vanderkerken, Karin ^a   De Leenheer, Evy ^a,b   Shipman, Claire ^b   Asosingh, Kewal ^a   Willems, Angelo ^a   Van Camp, Ben ^a   Croucher, Peter ^b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MORBIDITY; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOPROTEGERIN; PARAPROTEINEMIAS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS;

EID: 0037439916     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Giuliani, N., Bataille, R., Mancini, C., Lazzarretti, M., and Barillé, S. Myeloma cells induce imbalance in the osteopotegerin/osteoprotegerin ligand system in the human bone marrow microenvironment. Blood, 98: 3527-3533, 2001.
2. Pearse. R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., and Choi, Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA, 98: 11581-11586, 2001.
3. Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon-Mantel, A., Fermand, J. P., Milgrom, E., and Mariette, X. RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma. Br. J. Haematol., 117: 86-92, 2002.
4. Oyajobi, B. O., Traianedes, K., Yoneda, T., and Mundy, G. R. Expression of Rank ligand (RankL) by myeloma cells requires binding to the bone marrow stromal cells via an α4β1-VCAM-1 interaction [abstract]. Bone, 5: S180, 1998.
5. Shipman, C. M., Holen, I., Lippitt, J. M., Vandenberghe, E., and Croucher, P. I. Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood, 96: 360a, 2000.
6. Sezer, O., Heider, U., Jakob, C., Zavrski, I., Eucker, J., Possinger, K., Sers, C., and Krenn, V. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood, 99: 4646-4647, 2002.
7. Altamirano, C. B., Neeser, J. A., Manyak, S., Tang, Y. G., Sjak-Shie, N., Okopnik, J., Ma, M. H., Parker, K. M., Vescio, R., and Berenson, J. R. Malignant multiple myeloma cells expressing RANKL induce the formation of TRAP positive multinucleated cells [abstract]. Blood, 98: 637a, 2001.
8. Croucher, P. I., Shipman, C., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Crabbs, A. C., van Beek, E. J. R., Holen, I., Skerry, T., Dunstan, C., Russell, G. R., Van Camp, B., and Vanderkerken, K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98: 3534-3540, 2001.
9. Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., and Epstein, J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol., 116: 278-290, 2002.
10. Radl, J., De Glopper, E., Schuit, H. R., and Zurcher, C. Transplantation of the paraprotein-producing clone from old to young C57B1/LaLwRij mice. J. Immunol., 122: 609-613, 1979.
11. Asosingh, K., Radl, J., Van Riet, I., Van Camp, B., and Vanderkerken, K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol. J., 1: 351-356, 2000.
12. Vanderkerken, K., Asosingh, K., Bract, F., Van Riet, I., and Van Camp, B. Insulin like growth factor-I acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood, 93: 235-241, 1999.
13. Vanderkerken, K., De Raeve, H., Goes, E., Van Meirvenne, Radl, J., Van Riet, I., Thielemans, K., and Van Camp, B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br. J. Cancer. 76: 451-460, 1997.
14. Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G., and Croucher, P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti tumour activity. Br. J. Haematol., 98: 665-672, 1997.